Skip to main content
. 2017 Aug 11;24(12):2032–2043. doi: 10.1038/cdd.2017.125

Figure 6.

Figure 6

Reduction in MCL-1 levels does not cause cardio-, nephro- or hepato-toxicity. Histological analysis of H&E-stained sections of the (a) heart, (b) kidney and (c) liver of wild-type (wt) and Mcl-1+/− mice that had been left untreated or treated with 5-FU (day 21 post-treatment), doxorubicin (day 28 post-treatment), cytarabine (day 21 post-treatment) or dexamethasone (day 35 post-treatment) as indicated